RhumbLine Advisers
SYRE icon

RhumbLine Advisers’s Spyre Therapeutics SYRE Stock Holding History

RhumbLine Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Buy
94,763
+9,642
+11% +$704K 0.01% 1191
2026
Q1 		$4.29M Buy
85,121
+2,165
+3% +$81.6K ﹤0.01% 1474
2025
Q4 		$2.72M Buy
82,956
+12,042
+17% +$315K ﹤0.01% 1705
2025
Q3 		$1.19M Sell
70,914
-2,254
-3% -$36.8K ﹤0.01% 2155
2025
Q2 		$1.1M Buy
73,168
+17,145
+31% +$254K ﹤0.01% 2198
2025
Q1 		$904K Sell
56,023
-1,634
-3% -$34K ﹤0.01% 2223
2024
Q4 		$1.34M Buy
57,657
+3,722
+7% +$109K ﹤0.01% 2091
2024
Q3 		$1.59M Buy
53,935
+2,039
+4% +$56.8K ﹤0.01% 2027
2024
Q2 		$1.22M Buy
+51,896
New +$1.75M ﹤0.01% 2140
2022
Q2 		– Sell
-1,957
Closed -$113K – 3231
2022
Q1 		$113K Sell
1,957
-200
-9% -$16.8K ﹤0.01% 2868
2021
Q4 		$256K Sell
2,157
-9
-0.4% -$1.42K ﹤0.01% 2758
2021
Q3 		$430K Buy
2,166
+59
+3% +$10.3K ﹤0.01% 2615
2021
Q2 		$367K Buy
2,107
+254
+14% +$46.2K ﹤0.01% 2706
2021
Q1 		$367K Sell
1,853
-135
-7% -$25.9K ﹤0.01% 2627
2020
Q4 		$391K Buy
1,988
+175
+10% +$36.3K ﹤0.01% 2544
2020
Q3 		$321K Sell
1,813
-248
-12% -$45.9K ﹤0.01% 2488
2020
Q2 		$477K Buy
2,061
+543
+36% +$103K ﹤0.01% 2365
2020
Q1 		$177K Buy
1,518
+19
+1% +$3.23K ﹤0.01% 2628
2019
Q4 		$286K Buy
1,499
+7
+0.5% +$1.37K ﹤0.01% 2618
2019
Q3 		$287K Buy
1,492
+117
+9% +$22.8K ﹤0.01% 2600
2019
Q2 		$235K Buy
1,375
+410
+42% +$70.9K ﹤0.01% 2725
2019
Q1 		$194K Buy
965
+102
+12% +$21.3K ﹤0.01% 2754
2018
Q4 		$162K Buy
863
+283
+49% +$60K ﹤0.01% 2795
2018
Q3 		$139K Sell
580
-29
-5% -$6.77K ﹤0.01% 2816
2018
Q2 		$161K Buy
+609
New +$150K ﹤0.01% 2790

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

RhumbLine Advisers's SYRE Position: Q2 2026 in Review

RhumbLine Advisers increased its Spyre Therapeutics (SYRE) stake by 11% in Q2 2026, buying an estimated $704K and bringing the position to 94,763 shares worth $8.41M. The position accounts for 0.01% of the portfolio, ranked #1191.

RhumbLine Advisers first reported a position in SYRE in Q2 2018 and has held it in 25 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • RhumbLine Advisers held 94,763 shares of Spyre Therapeutics worth $8.41M as of Q2 2026.
  • RhumbLine Advisers bought 9,642 Spyre Therapeutics shares in Q2 2026, an estimated $704K.
  • Spyre Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1191 holding.
  • RhumbLine Advisers first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.